1. Identify the most pertinent emerging therapeutics in lymphoma and multiple myeloma and implement practice-changing data into their clinical practice.

2. Summarize the benefits and limitations of CAR-T transplantation for patients with relapsed multiple myeloma

3. Explain the differences between LOXO-305 and the currently available BTK inhibitors

4. Identify CAR-T options with promising clinical trial data versus already FDA approved for lymphoma

5. Outline the current available evidence for CNS relapse in DLBCL


Event address for attendees: https://uwmadison.webex.com/uwmadison/onstage/g.php?MTID=eaef33b9897f676cd1f88bc3551ccf887

Session date: 
01/06/2021 - 8:00am to 9:00am CST
Clinical Science Center, G5/119
600 Highland Ave
Madison, WI 53792
United States
  • 1.00 ACPE Contact Hours - Pharmacist
  • 1.00 AMA PRA Category 1 Credit
  • 1.00 ANCC Contact Hours
  • 1.00 University of Wisconsin–Madison Continuing Education Hours

Please login or register to take this course.
Discloser List CME Internal Report
Dr. Vaishalee Kenkre
Dr. Saurabh Rajguru
Dr. Priyanka Pophali
Dr. Tim Schmidt
Dr. Natalie Callander